Genetically Modified Microorganism and Its Use for the Production of D-chiro-inositol

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes genetically modified microorganisms that are engineered to efficiently convert myo-inositol or glucose-based sugars into D-chiro-inositol (DCI), an important compound with therapeutic potential for metabolic diseases like insulin resistance, type 2 diabetes, and polycystic ovary syndrome (PCOS). The invention involves the introduction of specific enzymatic pathways—NAD+-dependent and NADPH-dependent dehydrogenases—along with optimized transporters and regulatory modifications to increase yield, avoid unwanted byproducts, and enable flexible substrate usage. Additionally, it covers vectors, proteins, and nucleic acid sequences necessary for constructing these strains, as well as methods for industrial-scale DCI production.

Use CasesContent extracted from patent full text and abstract with AI.

• Biotechnological production of D-chiro-inositol for use as a nutraceutical or pharmaceutical ingredient.
• Manufacture of D-chiro-inositol for clinical applications in treating insulin resistance, type 2 diabetes, and PCOS.
• Production of D-chiro-inositol from cost-effective and widely available substrates (glucose or myo-inositol), improving accessibility to the compound.
• Development of industrial fermentation processes leveraging the engineered strains for commercial D-chiro-inositol supply.
• Sustainable alternatives to chemical synthesis methods, reducing environmental impact and production costs.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables efficient and cost-effective biotechnological production of D-chiro-inositol using inexpensive and widely available starting materials (like glucose or myo-inositol).
• Reduces reliance on environmentally harmful and expensive chemical synthesis processes, as it eliminates the need for harsh acids and minimizes hazardous waste.
• Allows for high-yield production due to optimized metabolic pathways and genetic engineering of the microorganisms, including improved substrate uptake and prevention of product degradation.
• Provides flexibility in the choice of microorganism and genetic constructs, accommodating various industrial bioprocess conditions and scales.
• Contributes to the pharmaceutical and nutraceutical industry by providing a stable, scalable, and sustainable D-chiro-inositol supply for metabolic disorders and reproductive health applications.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a genetically modified microorganism for the production of D-chiro-inositol from myo-inositol or sugars containing glucose building blocks, as well as vectors containing at least one NAD+- and one NADPH-dependent dehydrogenase for the conversion of myo-inositol to D-chiro-inositol. The present invention further relates to vectors containing at least one NAD+- and one NADPH-dependent dehydrogenase for the conversion of myo-inositol to D-chiro-inositol. Furthermore, the present invention relates to a method for the production of D-chiro-inositol. In addition, the present invention relates to uses of genetically modified microorganisms, vectors, proteins and nucleic acid sequences encoding them according to the invention for the production of D-chiro-inositol.